Bio-Techne, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard from Wells Fargo maintained a Buy rating on the stock and has a $59.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Couillard has given his Buy rating due to a combination of factors that highlight Bio-Techne’s potential for growth and financial stability. The company posted a solid revenue and earnings per share beat for the fourth quarter of 2025, driven by a 3% core growth, particularly in the Protein Sciences segment. This performance exceeded market expectations and suggests a strong operational foundation.
Moreover, the divestiture of the ExoDx business is seen as a strategic move that will enhance Bio-Techne’s operational margins by approximately 200 basis points, half of which is planned to be reinvested into growth areas. Despite some uncertainties in funding and pricing, the company’s prudent outlook for fiscal year 2026, with low single-digit core growth, is considered a conservative baseline with potential upside. These factors collectively support the Buy rating, indicating confidence in Bio-Techne’s ability to navigate challenges and capitalize on growth opportunities.
According to TipRanks, Couillard is a 5-star analyst with an average return of 13.2% and a 57.78% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Exact Sciences, and Bio-Techne.
In another report released yesterday, TD Cowen also initiated coverage with a Buy rating on the stock with a $65.00 price target.